Medela Reports Their Portable Medical Surgical and Airway Suction Devices Offers a Safer Alternative to Piped Vaccum Systems

Medela reports their healthcare mobile suction devices are a safer alternative to wall vacuum and can help expand critical care capacity and support UK hospitals in the fight against COVID-19.

Medela notes they have been used in Europe and worldwide. The company’s portable medical suction machines are designed to provide crucial suction and fluid removal during respiratory treatment provided with ventilators.

Traditionally, hospitals ensure a patient’s airway is clear by utilizing suction that relies on central wall piped vacuum. However, guidance published by the National Health Service (NHS) advises hospitals against using piped vacuum to support infectious disease units (IDU) to reduce the risk of virus spread and cross-contamination.

A previous study looking at contamination rates for wall-mounted suction units discovered contamination on over 30% of devices. Hence, portable medical suction machines are recommended for COVID-19 care. Medela offers a range of portable suction pumps which are available with a virus filter capable of reducing cross-contamination from COVID-19 with filtration efficiency of greater than 99.99987%.

These compact devices offer flexibility to hospitals while reducing the risk of viral transmission. When used with disposable collection systems, portable suction machines reduce staff exposure to hazardous fluids, while devices equipped with virus filters further reduce the risk of cross-contamination and viral exposure to staff.

Rob Rennel, Business Unit Manager at Medela comments: “Medela’s range of portable medical surgical and airway suction devices facilitate the removal of lung secretions in the inflammatory process of coronavirus – offering life-saving support to critical care patients while mitigating risks facing staff on the frontlines.”

Dr. Stephen Cole, Consultant in Intensive Care Medicine at Ninewells Hospital in Dundee, Scotland, adds: “The new reality is that we will need to rapidly increase intensive care units (ICU) bed capacity within 2- or 3-weeks’ notice. We need to prepare, need to plan, need to stock the hardware that we need such as ventilators, suction pumps, and monitors.”

While most patients with COVID-19 recover over time without the need for special treatment, in more critical cases the infection can trigger pneumonia, causing the lungs to become more inflamed and fill with fluid. Research shows approximately 14% of COVID-19 patients require hospitalization and oxygen support, while a further 5% require admission to an Intensive Care Unit (ICU) and supportive therapies such as intubation and ventilation.

Standard of care in the ICU requires each patient to be provided with a single suction device, which helps to decrease the risk of lung infections, prolonged hypoxia, and pooling of secretions in the lung.

SourceMedela

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”